Garbern Jessica C, Escalante Gabriela O, Lee Richard T
Department of Stem Cell and Regenerative Biology and the Harvard Stem Cell Institute, Harvard University, 7 Divinity Ave, Cambridge, MA 02138, United States; Department of Cardiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States.
Department of Stem Cell and Regenerative Biology and the Harvard Stem Cell Institute, Harvard University, 7 Divinity Ave, Cambridge, MA 02138, United States.
Trends Cardiovasc Med. 2021 Feb;31(2):85-90. doi: 10.1016/j.tcm.2020.01.002. Epub 2020 Jan 14.
Today, cell replacement therapy using pluripotent stem cell-derived cardiomyocytes (PSC-CMs) remains a research endeavor, with several hurdles that must be overcome before delivery of PSC-CMs can become a therapeutic reality. In this review, we highlight major findings to date from pre-clinical studies involving delivery of PSC-CMs and consider remaining challenges that must be addressed for successful clinical translation. Our goal is to provide an overview of the current status of cardiomyocyte replacement therapy and what challenges must be addressed before successful clinical translation of such therapies will be possible.
如今，使用多能干细胞衍生的心肌细胞（PSC-CMs）进行细胞替代疗法仍处于研究阶段，在PSC-CMs能够成为一种治疗手段之前，还有几个障碍必须克服。在这篇综述中，我们重点介绍了迄今为止涉及PSC-CMs递送的临床前研究的主要发现，并考虑了成功进行临床转化必须解决的剩余挑战。我们的目标是概述心肌细胞替代疗法的现状，以及在这种疗法成功进行临床转化之前必须解决哪些挑战。
